Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO in Predialysis Patients
NCT00701714Phase 3Terminated
- Sponsor
- Sandoz
- Start
- Sep 2007
- Primary completion
- Jul 2009
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 10
01
Overview
A Phase 3 trial of epoetin alfa in anemia of chronic kidney disease (CKD-A), sponsored by Sandoz. Started Sep 2007; status: terminated.
02
Drugs
epoetin alfa
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT00701714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00701714.